top of page
Alvion Bio Cell Line Platform
Advanced, ethically sourced amniotic stem cell lines designed for scalable therapeutic development and consisten outcomes.
The Amniotic Advantage
Alvion Bio utilizes a patented foundation centered on amniotic-derived stem cells. These cells bridge the gap between embryonic and adult stem cells, offering superior proliferation and pluripotency without the ethical or safety limitations of other sources.
- Ethically sourced and non-invasive collection
- High genomic and phenotypic stability
- Robust multi-lineage differentiation potential
- Proprietary expansion protocols ensuring batch consistency
Cell Banking Programme
Stage 01
Master Cell Bank (MCB)
- Fully characterized starting material
- Extensive viral and safety screening
- Preserved genomic integrity
Stage 02
Working Cell Bank (WCB)
- Standardized expansion protocols
- Validated for development manufacturing
- Scalable for global demand
Stage 03
Licensable Cell Lines
- Application-specific optimized lines
- Documentation package
- Ready for R&D integration
01
Isolation
Characterization
02
Operational Pipeline
03
Expansion
Quality Control
04
05
Distribution
Licensing & Access
Alvion Bio offers flexible licensing models for biopharmaceutical partners looking to accelerate their internal cell therapy pipelines. Our program is structured to support everything from early-stage discovery to global commercial manufacturing.
- Streamlined technology transfer protocols
- Full documentation and safety data
- Global exclusivity options for specific indications
- Rapid access to high-performance therapeutic cell lines
Platform at a Glance
99.9%
Viability Post-Thaw
Bioreactor
Ready for Large-Scale
bottom of page